First Horizon Advisors Inc. Sells 135 Shares of IQVIA Holdings Inc. (NYSE:IQV)

First Horizon Advisors Inc. lowered its position in IQVIA Holdings Inc. (NYSE:IQV) by 2.8% in the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 4,612 shares of the medical research company’s stock after selling 135 shares during the period. First Horizon Advisors Inc.’s holdings in IQVIA were worth $906,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Capital Performance Advisors LLP bought a new position in shares of IQVIA in the 3rd quarter worth approximately $27,000. Avior Wealth Management LLC raised its position in shares of IQVIA by 117.6% in the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock worth $38,000 after acquiring an additional 87 shares in the last quarter. Synergy Asset Management LLC bought a new position in shares of IQVIA in the 4th quarter worth approximately $33,000. Assetmark Inc. raised its position in shares of IQVIA by 612.5% in the 3rd quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock worth $54,000 after acquiring an additional 196 shares in the last quarter. Finally, Concord Wealth Partners purchased a new stake in shares of IQVIA in the 3rd quarter worth approximately $57,000. Institutional investors own 89.62% of the company’s stock.

Insider Buying and Selling

In related news, Director John G. Danhakl bought 1,275 shares of the firm’s stock in a transaction that occurred on Tuesday, December 3rd. The shares were bought at an average cost of $200.58 per share, with a total value of $255,739.50. Following the acquisition, the director now owns 1,275 shares in the company, valued at $255,739.50. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 1.60% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on IQV. UBS Group cut their price target on IQVIA from $260.00 to $255.00 and set a “buy” rating on the stock in a research note on Friday, February 7th. Stephens began coverage on IQVIA in a research note on Friday, December 20th. They issued an “overweight” rating and a $250.00 price target on the stock. Deutsche Bank Aktiengesellschaft cut their price target on IQVIA from $270.00 to $265.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. The Goldman Sachs Group cut their price target on IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Finally, TD Cowen cut their price target on IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Four research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $251.22.

IQVIA Stock Performance

IQV stock opened at $194.71 on Tuesday. The company has a market cap of $34.29 billion, a P/E ratio of 25.96, a price-to-earnings-growth ratio of 1.99 and a beta of 1.48. IQVIA Holdings Inc. has a 1 year low of $187.62 and a 1 year high of $261.73. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The stock’s fifty day moving average price is $199.52 and its 200-day moving average price is $215.96.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, equities analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.